Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (2019 - 2025)

Lyell Immunopharma's Shares Outstanding history spans 3 years, with the latest figure at $242.7 million for Q4 2021.

  • For Q4 2021, Shares Outstanding rose 1459.01% year-over-year to $242.7 million; the TTM value through Dec 2021 reached $242.7 million, up 1459.01%, while the annual FY2021 figure was $242.7 million, 1459.01% up from the prior year.
  • Shares Outstanding for Q4 2021 was $242.7 million at Lyell Immunopharma, up from $239.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $242.7 million in Q4 2021 and bottomed at $11.2 million in Q4 2019.
  • The 3-year median for Shares Outstanding is $238.5 million (2021), against an average of $149.6 million.
  • The largest annual shift saw Shares Outstanding surged 39.25% in 2020 before it skyrocketed 1459.01% in 2021.
  • A 3-year view of Shares Outstanding shows it stood at $11.2 million in 2019, then soared by 39.25% to $15.6 million in 2020, then surged by 1459.01% to $242.7 million in 2021.
  • Per Business Quant, the three most recent readings for LYEL's Shares Outstanding are $242.7 million (Q4 2021), $239.8 million (Q3 2021), and $238.5 million (Q2 2021).